The present study paves the way for further research into the potential clinical applications of Cu(ATSM) and similar compounds that target P-gp expression and function at the BBB and offers hope for the development of more effective drug therapies for neurodegenerative diseases such as AD. This evidence concerns the gene PGP and neurodegenerative disease.